With more than 30% of all deaths attributed to cardiovascular disease, the healthcare industry invests massively in disease prevention, treatment, and efforts to shorten the recovery period. But the extensive in vitro and in vivo testing required to ensure patient safety inevitably slows down cardiovascular device innovation.